Ascendia

  MARKET NEWS

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo
Orexo announces positive outcome from an in-vivo study of OX390
Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology
FUJIFILM Cellular Dynamics Launches New iPSC Manufacturing Facility in Madison
Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
VoxCell BioInnovation & adMare BioInnovations Partner to Advance Novel Antibody Therapies in a Human-Relevant Vascularized Tissue Platform

  EXPERT CONTENT & RESOURCES

 

Incorporating Self-Administered Drug-Device Combination Products Into Clinical Trials Can Bring Outsized Challenges & Outstanding Rewards

Incorporating Self-Administered Drug-Device Combination Products Into Clinical Trials Can Bring Outsized Challenges & Outstanding Rewards

The self-administered injectable drug-device combination (DDC) product market finds itself in the beginning stages of unprecedented therapeutic advancements. And all easy pharma buzzwords aside – “revolutionary,” “breakthrough,” “dedicated expertise” – the overarching reason for this paradigm shift boils down to one word: Necessity.

Avoiding Recalls: How to Ensure Sterility in Ophthalmic Products

Avoiding Recalls: How to Ensure Sterility in Ophthalmic Products

In the wake of several high-profile eye drop recalls, we look at the challenges of achieving sterility in ophthalmic products, the consequences of failing to do so, and how AbbVie Contract Manufacturing ensures product sterility and safety.

On-Demand Presentation: Analytical Strategy & Challenges for ADC

On-Demand Presentation: Analytical Strategy & Challenges for ADC

Global Vice President of Analytical & Research Development, Scott Zugel, spoke at Veranova’s SCALE Symposium, where he outlined key analytical strategies and challenges in ADC manufacturing in the pharmaceutical industry.

  FEATURED EDITORIAL

 

  COMPANY PROFILE

Bespak® is a global Contract Development and Manufacturing Organisation (CDMO) solely focused on inhaled and nasal drug delivery. Headquartered in Holmes Chapel, UK, the company develops and manufactures inhaled and nasal drug products, drug delivery devices and components for the global pharmaceutical industry. Bespak provides a specialist, fully integrated service to support customers from early-stage feasibility, analytical and formulation development, product development and clinical supply, through to full-scale cGMP batch production.

Click here for more.

  WHITEPAPERS & WEBINARS

WHITEPAPER - An Introduction to PLG Polymers for Long‑Acting Drug Delivery

WHITEPAPER - An Introduction to PLG Polymers for Long‑Acting Drug Delivery

Bioabsorbable poly(lactide-co‑glycolide) (PLG) polymers and poly(lactic acid-co-glycolic acid) (PLGA) have become an essential part of modern healthcare. Over the past five decades, these polymers have transformed how medicines are delivered – enabling long-acting injectables, implants, and localized drug‑delivery products …

WHITEPAPER - From Service Provider to Strategic Partner

WHITEPAPER - From Service Provider to Strategic Partner

By: Tom Sellig, CEO, Adare Pharma Solutions

As drug development grows more complex and timelines compress, sponsors require CDMO relationships built on integration, flexibility, and shared accountability. The relationship between pharmaceutical sponsors and their CDMO partners has undergone a fundamental …

WHITEPAPER - Stop Guessing. Start Predicting: Rethinking Early Oral Drug Development

WHITEPAPER - Stop Guessing. Start Predicting: Rethinking Early Oral Drug Development

Why Early Development Requires a Different Decision Model

Early oral drug development is an exercise in working under constraint. Teams are asked to make consequential decisions when materials are limited, timelines are tight, and the data are incomplete. Traditionally, formulation …

WHITEPAPER - Small Molecules: Choosing the Right Development Path

WHITEPAPER - Small Molecules: Choosing the Right Development Path

Summary

The white paper, Small Molecules: Choosing the Right Development Path, outlines a structured, risk-minimized approach to early CMC (Chemistry, Manufacturing, and Controls) development for small-molecule drugs—particularly for startups and virtual pharma companies with limited resources.

Key messages:

  • Start
…

WHITEPAPER - How Advanced Containment Technology Is Reshaping High-Potency API Micronization

WHITEPAPER - How Advanced Containment Technology Is Reshaping High-Potency API Micronization

       
By:
Harry Wade, Technical Associate, and Rosie Bird, EHS Lead, Catalent Dartford

The pharmaceutical industry faces a growing manufacturing challenge as therapeutic compounds become increasingly potent and targeted. Oncology and hormonal APIs, often designed for ultra-low dosing, promise meaningful clinical …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

June 3 – Pre-filled Syringes
June 10 – Inhalation drug Delivery
June 17 – Bioavailability
June 24 – Excipients